|
|
|
|
 Dr Anton Haselbeck,
VP, Head of New Technologies Roche Pharma Research, Germany Anton (Toni) Haselbeck is currently Head of New Technologies responsible for external access to technologies in the area of protein therapeutics at Roche Pharma Research in Penzberg.
Toni joined Roche in 1998 from Boehringer Mannheim where he started in 1988 as a Lab Head responsible for developing biochemical tools.
His major activities within Boehringer and then Roche have included the analysis of erythropoietin, and he directed as team leader all anaemia-related pre-clinical activities, including the development of CERA. As technical expert for erythropoietin he has played a major role in many legal and patent related activities world-wide. Besides his involvement in anaemia research and development, Toni was also responsible as Program Director for Oncology in Penzberg for in-licensing of products and technologies
Toni holds a Ph.D from then University of Regensburg and has spent two years as post doc at the University of California in Berkeley.Appearing: Conference Day Two: Thursday, 18 March 2010 09.10 Chairman’s opening remarks Dr Anton Haselbeck, VP, Head of New Technologies,
Roche Pharma Research, Germany 11.15 Technologies to develop optimal antibody therapeutic Dr Anton Haselbeck, VP, Head of New Technologies,
Roche Pharma Research, Germany |
|
|
|
|
|
Session sponsor:
Exhibitors:
|
asia research institution poster presentation
* For first 20 confirmed poster presentations
|
|
|
|
|
|
|
|
|
